{Reference Type}: Journal Article
{Title}: Cycle threshold predicted mortality in a cohort of patients with hematologic malignancies infected with SARS-CoV-2.
{Author}: Santarelli IM;Manzella DJ;Gallo Vaulet ML;Rodríguez Fermepín M;Crespo Y;Toledo Monaca S;Dobarro M;Fernández SI;
{Journal}: Rev Argent Microbiol
{Volume}: 55
{Issue}: 3
{Year}: 2023 Jul-Sep 26
{Factor}: 2.029
{DOI}: 10.1016/j.ram.2023.03.002
{Abstract}: When a SARS-CoV-2 RT-qPCR test is performed, it may determine an indirect measure of viral load called cycle threshold (Ct). Respiratory samples with Ct <25.0 cycles are considered to contain a high viral load. We aimed to determine whether SARS-CoV-2 Ct at diagnosis could predict mortality in patients with hematologic malignancies (lymphomas, leukemias, multiple myeloma) who contracted COVID-19. We included 35 adults with COVID-19 confirmed by RT-qPCR performed at diagnosis. We evaluated mortality due to COVID-19 rather than mortality due to the hematologic neoplasm or all-cause mortality. Twenty-seven (27) patients survived and 8 died. The global mean Ct was 22.8 cycles with a median of 21.7. Among the survivors, the mean Ct was 24.2, and the median Ct value was 22.9 cycles. In the deceased patients, the mean Ct was 18.0 and the median Ct value was 17.0 cycles. Using the Wilcoxon Rank Sum test, we found a significant difference (p=0.035). SARS-CoV-2 Ct measured in nasal swabs obtained at diagnosis from patients with hematologic malignancies may be used to predict mortality.